Intrabiotics!! Lohnt sich der Kauf noch?????? - 500 Beiträge pro Seite

[madmoep]

Hallo miteinander.

Hat vielleicht jemand neue Nachrichten über Intrabiotics.
Meiner Meinung eine sehr vielversprechende aktie.
Was meint ihr????

gruß madmoep

[frosch2000]

July 26, 2000

IntraBiotics Begins Additional Phase III Clinical Study for Protegrin
IB-367 In Patients Undergoing Radiation Therapy



MOUNTAIN VIEW, Calif., July 26, 2000 - IntraBiotics Pharmaceuticals, Inc.
(NASDAQ: IBPI), a biopharmaceutical company engaged in the development of
novel antibiotics, today said it has begun patient enrollment for the
second of two Phase III clinical trials related to one of its lead product
candidates, Protegrin IB-367. This trial is designed to demonstrate whether
Protegrin IB-367 can reduce the severity of oral mucositis in patients with
head and neck cancer who are undergoing radiation therapy. On May 4
IntraBiotics announced it had begun a similar Phase III trial, testing
Protegrin in patients receiving high-dose chemotherapy.

"We now have begun on schedule the second of two pivotal studies, which are
being conducted roughly in parallel with the goal of streamlining the time
to commercialization of this potential product," said Kenneth J. Kelley,
president and chief executive officer of IntraBiotics. "We hope to
demonstrate that Protegrin IB-367 can reduce the severity of the side
effect known as oral mucositis in cancer patients, regardless of whether
the side effect is caused by chemotherapy or radiotherapy."

Oral mucositis is a frequently occurring and debilitating condition
characterized by painful mouth ulcers that can form as a side effect of
cancer therapies. The clinical consequences of oral mucositis may include
pain, difficulty in talking, difficulty in swallowing and a corresponding
inability to eat. IntraBiotics previously reported positive findings from a
Phase II clinical trial in which Protegrin IB-367 reduced the severity of
oral mucositis in patients undergoing chemotherapy. The radiation therapy
Phase III study is targeted to enroll more than 370 patients at
approximately 35 treatment centers in North America and Europe. Albert
Clairmont, M.D., F.A.C.S., of Atlanta Ear, Nose and Throat Associates,
enrolled the first patient in the Phase III study.

Dr. Andy Trotti, Associate Professor and Director of Clinical Research in
Radiation Oncology at the University of South Florida`s H. Lee Moffitt
Cancer Center, said, "Oral mucositis is a serious medical problem for
patients receiving radiotherapy for head and neck cancers. Mucositis
greatly impacts nutrition and quality of life. It also represents a dose
and schedule-limiting toxicity of radiotherapy. There is an urgent need to
reduce the side effects of cancer therapy, thereby improving the patient`s
well-being and allowing clinicians to administer more effective treatment
regimens." Dr. Trotti is co-chair of the Phase III study steering committee
in addition to being an investigator in the study and co-chair of the
Radiation Therapy Oncology Group`s Head and Neck Committee.

Dr. Henry J. Fuchs, vice president of clinical affairs for IntraBiotics,
added, "Oral mucositis can be devastating to patients. Patients often
indicate that this complication is the most troubling side effect in cancer
treatment. We hope to be successful in better managing oral mucositis and
bringing relief to patients undergoing cancer therapy."

IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a biopharmaceutical
company engaged in the development of novel antibacterial and antifungal
drugs for the treatment and prevention of serious infectious diseases,
including those caused by multi-drug resistant microbes. The company`s
technology consists of several distinct chemical classes of antibacterials
and antifungals. In addition to Ramoplanin and Protegrin IB-367 Rinse now
in Phase III clinical studies, the company has several additional drug
candidates in earlier stage research and development. Additional
information is available at the company`s website: www.intrabiotics.com.

Certain statements in this press release contain forward-looking
information. As such, they are subject to the occurrence of many events
outside of IntraBiotics` control and are subject to various risk factors
that could cause IntraBiotics` results to differ materially from those
expressed in any forward-looking statement. The risk factors include,
without limitation, the inherent risks of product development failure, the
uncertainty of clinical outcomes, regulatory risks, and risks related to
proprietary rights, market acceptance and competition. These risk factors
are more fully described in documents on file with the Securities and
Exchange Commission including, but not limited to, our Registration
Statement on Form S-1 (No. 333-95461) and Quarterly Report on Form 10-Q for
the quarter ended March 31, 2000.

------------------------------------------------------
This service provided by Shareholder Direct.
Additional Information: http://www.intrabiotics.com

[Dollamen]

Intrabiotics ist auf jeden Fall eine gute Aktie.
Habe sie mir als Langfristaktie zugelegt und kann nur jeden empfehlen bei einem Kursrückgang für
Langfristanleger zuzuschlagen. Kurs ist ja gerade 7 % bei den Amis im Minus !